Compare · CRTX vs GILD
CRTX vs GILD
Side-by-side comparison of Cortexyme Inc. (CRTX) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRTX and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $187.10B, about 1047.2x CRTX ($178.7M).
- GILD has hit the wire 16 times in the past 4 weeks while CRTX has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 9 for CRTX).
- Company
- Cortexyme Inc.
- Gilead Sciences Inc.
- Price
- $1.94+1.84%
- $150.96+2.20%
- Market cap
- $178.7M
- $187.10B
- 1M return
- -
- +5.31%
- 1Y return
- -
- +32.89%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 1992
- News (4w)
- 0
- 16
- Recent ratings
- 9
- 25
Cortexyme Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest CRTX
- Cortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 4: Monohon Ted covered exercise/tax liability with 1,640 shares, decreasing direct ownership by 5% to 29,311 units to cover taxes
- SEC Form 10-Q filed by Cortexyme Inc.
- Cortexyme Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4: Monohon Ted covered exercise/tax liability with 1,520 shares, decreasing direct ownership by 5% to 30,951 units to cover taxes
- Cortexyme Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Stocks That Hit 52-Week Lows On Thursday
- Recap of Wednesday's Biotech Catalysts - End of The Day Summary
- Stocks That Hit 52-Week Lows On Wednesday
- Cortexyme Corporate Name Change To Quince Therapeutics To Take Effect On August 1, 2022
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 590 shares and covered exercise/tax liability with 285 shares, increasing direct ownership by 4% to 8,759 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,780 shares and covered exercise/tax liability with 4,230 shares, increasing direct ownership by 0.79% to 581,683 units (SEC Form 4)
- Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
- Chairman & CEO O'Day Daniel Patrick sold $2,229,592 worth of shares (15,000 units at $148.64) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 577,133 units (SEC Form 4)